https://www.selleckchem.com/pr....oducts/skf-34288-hyd
Ruxolitinib in vitro blocked activities of most of SLC transporters. Only OCT2 and MATE-2K may be however clinically inhibited by the JAK inhibitor, with the caution for OCT2 that in vitro inhibition data were generated with an FDA-non recommended fluorescent substrate. Ruxolitinib MATEs-mediated transport may additionally deserve attention for its possible pharmacological consequences in MATE-positive cells.A fixation preference for the affected eye is uncommon in patients with unilateral Duane retraction syndrome (DRS)
Like
Comment
Share
